Neuromielitis óptica. Actualización de los conceptos clínicos y fisiopatológicos de la enfermedad
Barra lateral del artículo
Contenido principal del artículo
Resumen
.
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Wingerchuk dM, lennon va, lucchinetti cF, et al. the spectrum of neuromyelitis optica. lancet neurol. 2007;6(9):805-15. DOI: https://doi.org/10.1016/S1474-4422(07)70216-8
Wingerchuk dM, Hogancamp WF, o’Brien Pc , et al. the clinical course of neuromyelitis optica (devic’s syndrome). neurology. 1999;53(5):1107-14. DOI: https://doi.org/10.1212/WNL.53.5.1107
Weinshenker BG. neuromyelitis optica: what it is and what it might be. lancet. 2003;361(9361):889-90. errata en: lancet. 2003;362(9383):582 DOI: https://doi.org/10.1016/S0140-6736(03)12784-5
albutt tc. on the ophthalmoscopic signs of spinal disease. lancet. 1870;1(2420):76-8. DOI: https://doi.org/10.1016/S0140-6736(02)68218-2
devic e. Myelite subague complique de nevrite optique. Bull Med. 1894;8:1033-4.
Jacob a, Matiello M, Wingerchuk dM, et al. neuromyelitis optica: changing concepts. J neuroimmunol. 2007;187(1-2):126-38. DOI: https://doi.org/10.1016/j.jneuroim.2007.04.009
Polman cH, reingold sc, edan G, et al. diagnostic criteria for multiple sclerosis: 2005 revisions to the “Mcdonald criteria”. ann neurol. 2005;58(6):840-6 DOI: https://doi.org/10.1002/ana.20703
cabre P, Heinzlef o, Merle H, et al. Ms and neuromyelitis optica in Martinique (French West indies). neurology. 2001;56(4):507-14. DOI: https://doi.org/10.1212/WNL.56.4.507
de seze J, lebrun c, stojkovic t, et al. is devic’s neuromyelitis optica a separate disease? a comparative study with multiple sclerosis. Mult scler. 2003;9(5):521-5. DOI: https://doi.org/10.1191/1352458503ms947oa
Ghezzi a, Bergamaschi r, Martinelli v, et al. clinical characteristics, course and prognosis of relapsing devic’s neuromyelitis optica. J neurol. 2004;251(1):47-52 DOI: https://doi.org/10.1007/s00415-004-0271-0
Wingerchuk dM, lennon va, Pittock sJ, et al. revised diagnostic criteria for neuromyelitis optica. neurology. 2006;66(10):1485-9. DOI: https://doi.org/10.1212/01.wnl.0000216139.44259.74
lennon va, Wingerchuk dM, Kryzer tJ, et al. a serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. lancet. 2004;364(9451):2106-12. DOI: https://doi.org/10.1016/S0140-6736(04)17551-X
lennon va, Kryzer tJ, Pittock sJ, et al. igG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J exp Med. 2005;202(4):473-7. DOI: https://doi.org/10.1084/jem.20050304
domingues rB, Kuster GW, lanes F, et al. recurrent neuromyelitis optica with diffuse central nervous system involvement: case report. arq neuropsiquiatr. 2004;62(2B):543-6. DOI: https://doi.org/10.1590/S0004-282X2004000300032
Jouhadi Z, ouazzani i, abid a, et al. neuromyelite optique de devic et hepatite virale a. a propos d’une observation pediatrique. rev neurol (Paris). 2004;160(12):1198-202 DOI: https://doi.org/10.1016/S0035-3787(04)71167-4
Papais-alvarenga rM, Miranda-santos cM, Puccioni-sohler M, et al. optic neuromyelitis syndrome in Brazilian patients. J neurol neurosurg Psychiatry. 2002;73(4):429-35. DOI: https://doi.org/10.1136/jnnp.73.4.429
Fukazawa t, Yamasaki K, ito H, et al. Both the Hla-c PB1 and -drB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. tissue antigens. 2000;55(3):199-205. DOI: https://doi.org/10.1034/j.1399-0039.2000.550302.x
Wingerchuk dM, Weinshenker BG. neuromyelitis optica: clinical predictors of a relapsing course and survival. neurology. 2003;60(5):848-53. DOI: https://doi.org/10.1212/01.WNL.0000049912.02954.2C
Pittock sJ, lennon va, Krecke K, et al. Brain abnormalities in neuromyelitis optica. arch neurol. 2006;63(3):390-6. DOI: https://doi.org/10.1001/archneur.63.3.390
roemer sF, Parisi Je, lennon va, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(Pt 5):1194-205 DOI: https://doi.org/10.1093/brain/awl371
nakashima i, Fujihara K, Miyazawa i, et al. clinical and Mri features of Japanese patients with multiple sclerosis positive for nMo-igG. J neurol neurosurg Psychiatry. 2006;77(9):1073-5. DOI: https://doi.org/10.1136/jnnp.2005.080390
Pittock sJ, Weinshenker BG, lucchinetti cF, et al. neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. arch neurol. 2006;63(7):964-8. DOI: https://doi.org/10.1001/archneur.63.7.964
Jarius s, Paul F, Franciotta d, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. nat clin Pract neurol. 2008;4(4):202-14. DOI: https://doi.org/10.1038/ncpneuro0764
nielsen s, nagelhus ea, amiry-Moghaddam M, et al. specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J neurosci. 1997;17(1):171-80 DOI: https://doi.org/10.1523/JNEUROSCI.17-01-00171.1997
Manley Gt, Fujimura M, Ma t, et al. aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. nat Med. 2000;6(2):159-63. DOI: https://doi.org/10.1038/72256
lehmann Hc, Hartung HP, Hetzel Gr, et al. Plasma exchange in neuroimmunological disorders: Part 1: rationale and treatment of inflammatory central nervous system disorders. arch neurol. 2006;63(7):930-5 DOI: https://doi.org/10.1001/archneur.63.7.930
Weinshenker BG, o’Brien Pc, Petterson tM, et al. a randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. ann neurol. 1999;46(6):878-86. DOI: https://doi.org/10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q
Falcini F, trapani s, ricci l, et al. sustained improvement of a girl affected with devic’s disease over 2 years of mycophenolate mofetil treatment. rheumatology (oxford). 2006;45(7):913-5. DOI: https://doi.org/10.1093/rheumatology/kei263
Weinstock-Guttman B, ramanathan M, lincoff n, et al. study of mitoxantrone for the treatment of recurrent neuromyelitis optica (d evic disease). arch neurol. 2006;63(7):957-63. DOI: https://doi.org/10.1001/archneur.63.7.957
cree B a, lamb s, Morgan K, et al. an open label study of the effects of rituximab in neuromyelitis optica. neurology. 2005;64(7):1270-2 DOI: https://doi.org/10.1212/01.WNL.0000159399.81861.D5